Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | DTYMK | P23919 | 4/20 | 0.62 |
| ▸ | TK1 | P04183 | 3/20 | 0.59 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | POLD1 | P28340 | 1/20 | 0.56 |
| ▸ | TYMS | P04818 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153654 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 | |
| SCHEMBL14262431 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 | |
| SCHEMBL1521074 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 | |
| SCHEMBL1521023 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 | |
| SCHEMBL1520996 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 | |
| SCHEMBL1521353 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 | |
| SCHEMBL15756213 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 | |
| SCHEMBL1521215 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 | |
| SCHEMBL1521248 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 | |
| SCHEMBL4077326 | 0.93 | POLB (0.63) | POLBDTYMKTK1POLA1POLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906460-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER (US) | 2011-03-15 | — | — | US | claimed |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-08-02 | — | — | US | claimed |
| US-20050266523-A1 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2005-12-01 | — | — | US | claimed |
| US-6884604-B2 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-04-26 | — | — | US | claimed |
| US-20030068669-A1 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-04-10 | — | — | US | claimed |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-03-20 | — | — | US | claimed |
| WO-2002079150-A2 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2002048331-A2 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLTRANSFERASES AND ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND 'UNNATURAL' UDP- AND NUCLEOTIDE SUGARS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-20 | — | — | WO | claimed |
| US-8618269-B2 | Glycorandomization and production of novel novobiocin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8198419-B2 | Glycorandomization and production of novel erythromycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | THORSON JON | 2011-05-26 | — | — | US | disclosed |
| US-7906460-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-6884604-B2 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040259228-A1 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-12-23 | — | — | US | disclosed |
| US-20030068669-A1 | Glycorandomization and the production of novel erythronolide and coumarin analogs | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-04-10 | — | — | US | disclosed |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-03-20 | — | — | US | disclosed |
| WO-2002079150-A2 | GLYCORANDOMIZATION AND THE PRODUCTION OF NOVEL ERYTHRONOLIDE AND COUMARIN ANALOGS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002048331-A2 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLTRANSFERASES AND ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND 'UNNATURAL' UDP- AND NUCLEOTIDE SUGARS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | POLB 1506/4885DTYMK 157/4885TK1 772/4885 |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | PNP, NUDT14, ENTPD5 | POLB 1815/4885DTYMK 75/4885TK1 190/4885 |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | PNP, NUDT14, NUDT5 | POLB 1984/4885DTYMK 62/4885TK1 158/4885 |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | NMT2, NMT1, NAMPT | POLB 898/4885DTYMK 134/4885TK1 450/4885 |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | POLB 1627/4885DTYMK 156/4885TK1 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.